UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 218

Sortiert nach

Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐Naive Patients With Moderately‐to‐Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Multicenter, Multi‐Country, Randomized, Double‐Blind, Active Comparator–Controlled Trial

Arthritis & rheumatology (Hoboken, N.J.), 2020-10, Vol.72 (10), p.1607-1620

2020

Volltextzugriff (PDF)

Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials

Journal of clinical pharmacology, 2020-04, Vol.60 (4), p.528-539

2020

Volltextzugriff (PDF)

Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib

Journal of clinical pharmacology, 2020-02, Vol.60 (2), p.188-197

2020

Volltextzugriff (PDF)

Use of Clinical Trial Simulations to Compare the Performance of Different Approaches for Population Analyses of Pediatric Pharmacokinetic Data

Journal of clinical pharmacology, 2023-07, Vol.63 (7), p.859-868

2023

Volltextzugriff (PDF)

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

The Lancet (British edition), 2018-06, Vol.391 (10139), p.2513-2524

2018

Volltextzugriff (PDF)

The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects

Journal of clinical pharmacology, 2019-04, Vol.59 (4), p.510-516

2019

Volltextzugriff (PDF)

Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics

Journal of clinical pharmacology, 2019-09, Vol.59 (9), p.1188-1194

2019

Volltextzugriff (PDF)

Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail

Journal of clinical pharmacology, 2020-01, Vol.60 (1), p.86-95

2020

Volltextzugriff (PDF)

Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high‐fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib

British journal of clinical pharmacology, 2017-10, Vol.83 (10), p.2242-2248

2017

Volltextzugriff (PDF)

Upadacitinib: Mechanism of action, clinical, and translational science

Clinical and translational science, 2024-01, Vol.17 (1), p.e13688-n/a

2024

Volltextzugriff (PDF)

Exposure‐Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis—Analyses of Phase 2b Study to Support Selection of Phase 3 Doses

Journal of clinical pharmacology, 2021-05, Vol.61 (5), p.628-635

2021

Volltextzugriff (PDF)

Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

Journal of allergy and clinical immunology, 2020-03, Vol.145 (3), p.877-884

2020

Volltextzugriff (PDF)

Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials

Clinical and translational science, 2022-01, Vol.15 (1), p.267-278

2022

Volltextzugriff (PDF)

Therapeutic Protein Drug Interaction Potential in Subjects With Psoriasis: An Assessment Based on Population Pharmacokinetic Analyses of Sensitive Cytochrome P450 Probe Substrates

Journal of clinical pharmacology, 2021-03, Vol.61 (3), p.307-318

2021

Volltextzugriff (PDF)

Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease

Gastroenterology (New York, N.Y. 1943), 2020-06, Vol.158 (8), p.2123-2138.e8

2020

Volltextzugriff (PDF)

Exposure–Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit–Risk Assessment in Rheumatoid Arthritis

Clinical pharmacology and therapeutics, 2020-04, Vol.107 (4), p.994-1003

2020

Volltextzugriff (PDF)

Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease

The New England journal of medicine, 2023-05, Vol.388 (21), p.1966-1980

2023

Volltextzugriff (PDF)

Inclusion of Adolescents With Adults in Phase 3 Clinical Trials: Overview of the Current State and a Call for Action

Journal of clinical pharmacology, 2020-05, Vol.60 (5), p.559-562

2020

Volltextzugriff (PDF)

Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication

Clinical pharmacokinetics, 2020-05, Vol.59 (5), p.531-544

2020

Volltextzugriff (PDF)

Are Clinical Therapeutic Protein‐Drug Interaction Studies Needed When Disease Modification Is Driving the Potential Interaction?

Journal of clinical pharmacology, 2018-10, Vol.58 (10), p.1371-1372

2018

Volltextzugriff (PDF)

Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials

Clinical pharmacokinetics, 2018-08, Vol.57 (8), p.977-988

2018

Volltextzugriff (PDF)

Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis

Clinical pharmacokinetics, 2016-12, Vol.55 (12), p.1547-1558

2016

Volltextzugriff (PDF)

Exposure–Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended‐Release Formulation

Clinical pharmacology and therapeutics, 2020-03, Vol.107 (3), p.639-649

2020

Volltextzugriff (PDF)

Use of Early Clinical Trial Data to Support Thorough QT Study Waiver for Upadacitinib and Utility of Food Effect to Demonstrate ECG Assay Sensitivity

Clinical pharmacology and therapeutics, 2018-05, Vol.103 (5), p.836-842

2018

Volltextzugriff (PDF)

Pharmacokinetics and Exposure–Response Analyses to Support Dose Selection of Upadacitinib in Crohn's Disease

Clinical pharmacology and therapeutics, 2024-07

2024

Volltextzugriff (PDF)

1 – 25 von 218

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(187)
Mit Volltextzugriff
(186)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(13)

Menü

Weitere Dienste

Einstellungen

Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐Naive Patients With Moderately‐to‐Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Multicenter, Multi‐Country, Randomized, Double‐Blind, Active Comparator–Controlled Trial

Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials

Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib

Use of Clinical Trial Simulations to Compare the Performance of Different Approaches for Population Analyses of Pediatric Pharmacokinetic Data

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects

Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics

Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail

Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high‐fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib

Upadacitinib: Mechanism of action, clinical, and translational science

Exposure‐Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis—Analyses of Phase 2b Study to Support Selection of Phase 3 Doses

Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials

Therapeutic Protein Drug Interaction Potential in Subjects With Psoriasis: An Assessment Based on Population Pharmacokinetic Analyses of Sensitive Cytochrome P450 Probe Substrates

Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease

Exposure–Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit–Risk Assessment in Rheumatoid Arthritis

Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease

Inclusion of Adolescents With Adults in Phase 3 Clinical Trials: Overview of the Current State and a Call for Action

Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication

Are Clinical Therapeutic Protein‐Drug Interaction Studies Needed When Disease Modification Is Driving the Potential Interaction?

Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials

Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis

Exposure–Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended‐Release Formulation

Use of Early Clinical Trial Data to Support Thorough QT Study Waiver for Upadacitinib and Utility of Food Effect to Demonstrate ECG Assay Sensitivity

Pharmacokinetics and Exposure–Response Analyses to Support Dose Selection of Upadacitinib in Crohn's Disease

Suchergebnisse filtern